This represents a multi-pathway approach that may be considered in certain clinical situations - but whether it offers advantages over individual prescriptions for your specific health profile is a determination that should be discussed with a prescribing provider, not decided based on marketing
Your provider will evaluate your baseline metabolic health, kidney function, and other clinical factors before recommending any therapeutic approach
A person must also be at least 18 years old and meet one of the following criteria: Have a body mass index (BMI) of at least 35 at the time they begin the GLP-1 medication Have a BMI of at least 30 at the time of beginning the medication and at least one of the following diagnoses: Heart failure with preserved ejection fraction Uncontrolled hypertension Chronic kidney disease (stage 3a or above) Have a BMI of at least 27 at the time of beginning the medication and at least one of the following diagnoses: Pre-diabetes Previous heart attack Previous stroke Symptomatic peripheral artery disease Anyone who meets these qualifications but is eligible to receive GLP-1 coverage under Part D for another condition, like type 2 diabetes, wont qualify for the Bridge program, CMS says
There was this incredible science and an opportunity to be in a category which is just so large but has a lot of quackery in it. Kennedy raised money, built a team and launched Calocurb as a direct-to-consumer product in 2018three years before the FDA approved Wegovy as the first GLP-1 agonist to be used for chronic weight management and two years before New Zealands strict border management in response to the COVID effectively isolated the country and its businesses from the rest of the world
Still, seeing a pattern of lower overall healthcare use may give patients hope that these medications could offer benefits beyond metabolic effects and highlights the need for future prospective studies to determine whether GLP1RAs truly help with migraine prevention
